AstraZeneca PLC (AZN)vsElevai Labs, Inc. Common Stock (ELAB)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
ELAB
Elevai Labs, Inc. Common Stock
$1.54
-8.88%
HEALTHCARE · Cap: $7.00M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4751020% more annual revenue ($60.44B vs $1.27M). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
ELAB
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for ELAB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ELAB
The strongest argument for ELAB centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : ELAB
The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while ELAB is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 25/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Elevai Labs, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Elevai Labs, Inc. (Ticker: ELAB) is an innovative technology firm specializing in artificial intelligence and machine learning solutions that drive transformative efficiencies in various industries, notably healthcare and finance. By leveraging sophisticated data analytics platforms, Elevai Labs empowers organizations to make informed decisions and unlock actionable insights from intricate datasets. Positioned strategically within the burgeoning tech landscape, the company is poised to leverage emerging market trends, offering substantial value and operational improvements to clients and stakeholders alike. Its commitment to advancing AI-driven technologies underscores Elevai Labs' potential for sustainable growth and competitive advantage.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?